Kenoki Ohuchida1, Takao Ohtsuka2, Kazuhiro Mizumoto2, Makoto Hashizume3, Masao Tanaka2. 1. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ; Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 2. Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 3. Department of Advanced Medical Initiatives, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract
BACKGROUND: Improvement in the prognosis of patients with pancreatic cancer, novel effective screening and diagnostic strategies and treatments are needed. Recent advances in the understanding of pancreatic carcinogenesis and tumor microenvironment have allowed identification of biomarkers for screening, diagnosis and prediction of cancer treatments, including novel therapies targeting specific cancer or stromal cell subpopulations. Personalized therapy in pancreatic cancer is also promising as several drugs such as S1, capecitabine and gemcitabine reportedly have significant therapeutic effects. Predictive markers are thus needed to select patients most likely to benefit from therapies based on gemcitabine or other drugs. SUMMARY: We review the clinical significance of promising screening, diagnostic, predictive and prognostic biomarkers based on genetic and epigenetic alterations and microRNA abnormalities in pancreatic cancer. We also review new types of biomarkers based on stromal cells, such as pancreatic stellate cells, in the microenvironment of pancreatic cancer.
BACKGROUND: Improvement in the prognosis of patients with pancreatic cancer, novel effective screening and diagnostic strategies and treatments are needed. Recent advances in the understanding of pancreatic carcinogenesis and tumor microenvironment have allowed identification of biomarkers for screening, diagnosis and prediction of cancer treatments, including novel therapies targeting specific cancer or stromal cell subpopulations. Personalized therapy in pancreatic cancer is also promising as several drugs such as S1, capecitabine and gemcitabine reportedly have significant therapeutic effects. Predictive markers are thus needed to select patients most likely to benefit from therapies based on gemcitabine or other drugs. SUMMARY: We review the clinical significance of promising screening, diagnostic, predictive and prognostic biomarkers based on genetic and epigenetic alterations and microRNA abnormalities in pancreatic cancer. We also review new types of biomarkers based on stromal cells, such as pancreatic stellate cells, in the microenvironment of pancreatic cancer.
Authors: Max G Bachem; Shaoxia Zhou; Karin Buck; Wilhelm Schneiderhan; Marco Siech Journal: Langenbecks Arch Surg Date: 2008-01-17 Impact factor: 3.445
Authors: Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone Journal: Cancer Res Date: 2007-02-01 Impact factor: 12.701
Authors: Kathleen M Murphy; Kieran A Brune; Constance Griffin; Jennifer E Sollenberger; Gloria M Petersen; Ravi Bansal; Ralph H Hruban; Scott E Kern Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: Andrew V Biankin; James G Kench; Emily K Colvin; Davendra Segara; Christopher J Scarlett; Nam Q Nguyen; David K Chang; Adrienne L Morey; C-Soon Lee; Mark Pinese; Samuel C L Kuo; Johana M Susanto; Peter H Cosman; Geoffrey J Lindeman; Jane E Visvader; Tuan V Nguyen; Neil D Merrett; Janindra Warusavitarne; Elizabeth A Musgrove; Susan M Henshall; Robert L Sutherland Journal: Gastroenterology Date: 2009-04-16 Impact factor: 22.682
Authors: Song Wang; Cecilie L Bager; Morten A Karsdal; Dimitrios Chondros; Darin Taverna; Nicholas Willumsen Journal: J Transl Med Date: 2021-01-21 Impact factor: 5.531